Navigation Links
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Date:10/21/2008

ROCKVILLE, Md., Oct. 20 /PRNewswire/ -- Glycotex, Inc. today announced enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area.

A previous Phase II Pilot Study, investigating clinical outcomes and safety parameters of GLYC-101 at two doses compared to placebo was completed in April 2008.

The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients will be randomized to receive either GLYC-101 0.1% or GLYC-101 1.0% gel on one lower eyelid, and placebo on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter. The primary efficacy endpoint of the study is time to wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study will observe the effects of the topical agent over the course of one month following the initial treatment with the investigational compound and placebo.

About GLYC-101

GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate is a topical gel to be applied directly on the wound surface. In May 2006, Glycotex completed a Phase II clinical trial of GLYC-101 in Australia, in which GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101.

The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.

About Glycotex, Inc.

Glycotex, Inc
'/>"/>

SOURCE Glycotex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. PURE Bioscience Reports Fourth Quarter and Year End Results
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008
5. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
6. Neptune Technologies & Bioressources Inc. reports first quarter results
7. CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Cell,Genesys, Inc. (Nasdaq: CEGE ), today announced ... and Sharon E. Tetlow, senior,vice president and chief financial ... to the company,s third quarter financial results,that will be ... at 2:00 p.m. PT/ 5:00 p.m. ET. The ...
... Include World-Renowned RNase and RNA Researchers, SOMERSET, ... of ribonuclease (RNase) therapeutics will be the focus ... by Alfacell,Corporation (Nasdaq: ACEL ). Moderated ... officer, and David Sidransky, M.D., Alfacell,s scientific,advisory board ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... UT Southwestern neuroscience researchers have identified a gene that controls ... mice often used to study addiction and behavior patterns. ... , determines how mammals respond to cocaine, although it is ... or for addiction, said Dr. Joseph Takahashi , chair ...
... Department of Energy,s Brookhaven National Laboratory have identified a ... class of plant products with a wide range of ... source of flavors, fragrances, and pigments; some are of ... contribution to the construction of plant cell walls, (poly)phenols ...
... of superstars in the materials world. Already prized for ... identity, vanadium dioxide can now add muscle power to ... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... from vanadium dioxide that for its size is a ...
Cached Biology News:UT Southwestern neuroscience researchers identify gene involved in response to cocaine 2Enlisting cells' protein recycling machinery to regulate plant products 2A micro-muscular breakthrough 2A micro-muscular breakthrough 3